摘要
目的分析达格列净在2型糖尿病(T2DM)合并代谢相关脂肪性肝病(MAFLD)患者中治疗效果及对代谢指标及自主神经功能的影响。方法筛选该院于2020年1月—2021年12月收治的74例T2DM合并MAFLD患者作为研究对象展开分析,每组37例。对比组采用常规降糖治疗,研究组在对比组基础上联合达格列净治疗,比较两组治疗疗效、代谢指标。结果研究组治疗总有效率94.60%明显较对比组75.68%更高,差异有统计学意义(P<0.05)。治疗后,研究组空腹血糖(FPG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDC-C)、胰岛素抵抗指数(HOMA-IR)水平较对比组更低,高密度脂蛋白胆固醇(HDL-C)、胰岛β细胞功能指数(HOMA-β)均较对比组更高,差异有统计学意义(P<0.05)。结论在T2DM合并MAFLD患者临床治疗期间,联合达格列净,可提高治疗疗效,且有助更好改善代谢指标、胰岛功能。
Objective To analyze the therapeutic effect of dapagliflozin in patients with type 2 diabetes mellitus(T2DM)complicated with metabolic-associated fatty liver disease(MAFLD)and its effects on metabolic indexes and autonomic nerve function.Methods A total of 74 patients with T2DM combined with MAFLD admitted to the hospital from January 2020 to December 2021 were selected as the research subjects for analysis,with 37 cases in each group.The control group was treated with conventional hypoglycemic therapy,and the study group was treated with dapagliflozin on the basis of the control group,and the therapeutic efficacy and metabolic indexes of the two groups were compared.Results The total effective rate of the study group was 94.60%,which was significantly higher than that of the control group 75.68%,and the difference was statistically significant(P<0.05).After treatment,fasting blood glucose(FPG),2 h postprandial blood glucose(2 hPG),glycosylated hemoglobin(HbA1c),total cholesterol(TC),triacylglycerol(TG),low density lipoprotein cholesterol(LDC-C),the levels of insulin resistance index(HOMA-IR)in the study group were lower than those in the control group,and high-density lipoprotein cholesterol(HDL-C)and pancreatic islet beta cell function index(HOMA-β)were higher than those in the control group,and the difference was statistically significant(P<0.05).Conclusion During the clinical treatment of T2DM patients with MAFLD,the combination of dapagliflozin can improve the therapeutic effect,and help to better improve metabolic indexes and islet function.
作者
周秀萍
ZHOU Xiuping(Department of Pharmacy,Siming Campus,the First Affiliated Hospital of Xiamen University,Xiamen,Fujian Province,361001 China)
出处
《糖尿病新世界》
2022年第9期75-77,85,共4页
Diabetes New World Magazine
关键词
2型糖尿病
代谢相关脂肪性肝病
达格列净
代谢指标
Type 2 diabetes mellitus
Metabolic-related fatty liver disease
Dapagliflozin
Metabolic indicators
